Decoy Therapeutics Inc. (DCOY)
Nasdaq · Healthcare · Biotechnology
$1.67−5.65%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $1.1M
- P/E (trailing)
- 0.1
- 52-week range
- $1.61 – $55.92
- 52-week change
- −96.74%
- EPS (trailing)
- $12.74
- Analyst rating
- 1.0 Strong buy
Fiscal year to Dec 2025
- Net income
- $12.5M
- Diluted EPS
- −$129.10
- Free cash flow
- −$5.4M
From the company’s annual report on SEC EDGAR.
About Decoy Therapeutics Inc.
Decoy Therapeutics Inc. operates as a pre-clinical stage biotechnology company. It focuses on advancing the peptide conjugate therapeutics through its Immediate Peptide/PPMO/P-PROTAC Alpha-helical Conjugate Technology (IMP3ACT) platform that leverages peptide coiled-coils chemistry and physics to design a-helical peptides through computational and ML tools. The company's IMP3ACT platform leverages machine learning and artificial intelligence tools alongside synthesis techniques to engineer, enhance, and manufacture peptide conjugates targeting various unmet medical needs. It focuses on building a portfolio of peptide conjugate therapeutics focusing on infectious diseases and oncology. The company was formerly known as Salarius Pharmaceuticals, Inc. and change its name to Decoy Therapeutics Inc. in January 2026. Decoy Therapeutics Inc. is based in Houston, Texas.
Headquarters: Houston, United States · 11 employees · decoytx.com